The total number of records retrieved from this search are 5. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_1258	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationYes	Virus aloneNo	Virus in combination with drug/radiationVSV in combination with cisplatin (0.1 microgram/ml)	Immune gene insertion in viral genomeVirus expressing IL-12 gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC3H/HeJ female mice orthotopic for SSC VII cell line	In-vivo virus concentration5.0E+8 pfu per kg	In-vivo toxicityNA	In-vivo resultTumor size decreases to 0.5 cm² after 20 days	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18043494
IDOV_1259	Virus nameVesicular stomatitis virus	Virus strainFusogenic strain	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationYes , expressing fusion protein	Virus aloneNo	Virus in combination with drug/radiationVSV in combination with cisplatin (0.1 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC3H/HeJ female mice orthotopic for SSC VII cell line	In-vivo virus concentration1.0E+7 pfu per kg	In-vivo toxicityNA	In-vivo resultTumor size decreases to 0.5 cm² after 20 days	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18043494
IDOV_4489	Virus nameHerpes simplex virus	Virus strainRH2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma 34.5 gene and gB gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC3H mice subcutaneous implanted for SCCVII (1.0E+6)	In-vivo virus concentration50 microliter of RH2 virus, 3 times at interval of 2 days	In-vivo toxicityNA	In-vivo resultTumor volume was less than 1587 cubic mm in treated mice compared to control 2996 cubic mm after 25 days	Mode of deliveryIntratumoral	Pathway inducedVirus induced apoptosis	Immunogenic effectIncreased extracellular ATP and HMGB1, indicating immunogenic cell death	Clinical trialNA	PMID26987291
IDOV_5680	Virus nameReovirus	Virus strainReovirus strain T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC3H mice xenografted for ras transformed C3H cell line (1.0E+6)	In-vivo virus concentration5.0E+8 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 60mm after 24 days	Mode of deliveryIntravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS7964187
IDOV_5681	Virus nameReovirus	Virus strainReovirus strain T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with cisplatin (2.5 mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC3H mice xenografted for ras transformed C3H cell line (1.0E+6)	In-vivo virus concentration5.0E+8 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 22mm after 24 days	Mode of deliveryIntravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS7964187